BioCentury | Jun 28, 2018
Distillery Therapeutics

Endocrine/Metabolic

...a prodrug of indoximod, in Phase I testing for solid tumors. Tempest Therapeutics Inc. has TPST-8844...
BioCentury | Mar 30, 2018
Financial News

Versant launches Tempest with $70M

...Inception that does not follow the build-to-buy model (see BioCentury, March 28 ). Lead candidate TPST-8844...
BioCentury | Mar 28, 2018
Financial News

Versant launches Tempest with $70M

...Inception that does not follow the build-to-buy model (see BioCentury, March 28) . Lead candidate TPST-8844...
...Robert Weisskoff and Quan's Stella Xu joined Tempest's board. Virginia Li Indoleamine 2,3-dioxygenase (IDO) (INDO) PPAR alpha Tempest Therapeutics Inc. TPST-1120 TPST-8844 Versant...
BioCentury | Mar 28, 2018
Finance

Versant’s independent streak

...testing, and a third into the clinic, in the next three years. The most advanced, TPST-8844...
...the clinic in the next 12 months. CEO Tom Dubensky said Tempest plans to evaluate TPST-8844...
...Highline Therapeutics (see BioCentury, Feb. 27) . Virginia Li, Assistant Editor Indoleamine 2,3-dioxygenase (IDO) (INDO) PPAR alpha Tempest Therapeutics Inc. TPST-1120 TPST-8844 Versant...
Items per page:
1 - 4 of 4